UNSPSC 51351526: Pregnenolone methyl ether

This classification denotes a therapeutic progestin with the molecular formula C22H34O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TU767RK7YN, chemically known as pregn-5-en-20-one, 3-methoxy-, (3.beta.)-, but more generally known as pregnenolone methyl ether, which bears US NIH Compound Identifier 233254. European Medicines Agency schedules pregnenolone methyl ether or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10024MIG.

Most nations, for tariff purposes, schedule pregnenolone methyl ether under HS 29372900. SMILES: CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)OC)C)C.

UNSPSC 51351526 Pregnenolone methyl ether is a Commodity code covering pharmaceutical active ingredients and chemical compounds used in drug manufacturing and healthcare delivery across state and local facilities. The scope of work under this code encompasses the supply of generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesalers to participating state and local government healthcare systems, laboratories, and medical facilities. State and local government buyers under this code include state departments of administration, state procurement offices administering cooperative purchasing agreements, and participating local government healthcare facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, exemplifies the issuing-body structure for this commodity — cooperative purchasing vehicles that coordinate pharmaceutical procurement across multiple participating jurisdictions to leverage volume discounts and standardize product sourcing.

The most recent activity under this code centers on the Upper Midwest and Pacific Northwest. MMCAP issued a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, serving participating state and local facilities in Minnesota and Oregon. The solicitation requires manufacturers to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded vendors effective July 1, 2026. Vendors must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with at least two of the three authorized wholesalers, and demonstrate pricing flexibility through flat price, net price formats, or WAC-minus structures. The contract term is two years for new responders with optional extensions, and all products must comply with FDA requirements with expiration dates of at least one year from manufacture and a minimum six-month shelf life.